## Core Concept
Imiglucerase, marketed under the brand name Cerezyme, is an enzyme replacement therapy used to treat a specific lysosomal storage disorder. This disorder results from a deficiency of a particular enzyme, leading to the accumulation of harmful quantities of a certain lipid within cells. The condition primarily affects various organs, including the liver, spleen, and bones.

## Why the Correct Answer is Right
Imiglucerase (Cerezyme) is specifically designed to replace the deficient enzyme **glucocerebrosidase**. This enzyme deficiency is characteristic of **Gaucher's disease**, a genetic disorder that leads to the accumulation of glucocerebroside within cells, particularly affecting the spleen, liver, and bone marrow. By administering imiglucerase, the levels of functional glucocerebrosidase are increased, which helps in breaking down glucocerebroside, thereby reducing its accumulation and alleviating the symptoms of Gaucher's disease.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because imiglucerase is not used for the treatment of a condition related to the deficiency of another enzyme.
- **Option B:** This option is incorrect as it does not accurately represent the condition treated by imiglucerase.
- **Option C:** This option might seem plausible but is incorrect because imiglucerase specifically targets Gaucher's disease, not the condition described here.

## Clinical Pearl / High-Yield Fact
A key point to remember is that Gaucher's disease is categorized into three types: Type 1 (the most common form, with a wide range of symptoms and age of onset), Type 2 (acute neuronopathic, with severe symptoms), and Type 3 (subacute neuronopathic). Imiglucerase is primarily used for the treatment of Type 1 Gaucher's disease, significantly improving the quality of life for patients by reducing organomegaly and improving hematologic parameters.

## Correct Answer: D. Gaucher's disease.